Safety and immuno-modulation evaluation of treatment with intravenous and spinal cord injections of of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis (ALS).

Mashhad University of Medical Sciences0 sites15 target enrollmentTBD

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Not specified
Sponsor: Mashhad University of Medical Sciences
Enrollment: 15
Status: Recruiting
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Mashhad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

•Patients with ALS approved by neurologist with 31\-46 ALSFRS\-R score
•Patients should be treated with a fixed dose of Rilozule 3 months ago.
•Patients should not be detrimental to any other chronic disease and do not use ventilator.

Exclusion Criteria

•Patients with malignancy
•Patients with other chronic disruptive diseases
•Others Neurodegenerative disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Phase 2

To study the effect of Swarnaprashan in reducing the frequency of illness in children by improving the immunity and increasing the body strength.

CTRI/2021/05/033713ational Institute of Ayurveda Jaipur Rajasthan30

Not yet recruiting

Not Applicable

Investigate the safety and efficacy of small cell lung cancer,Kidney cancer and Primary liver cancer immunotherapyHistopathologically confirmed small cell lung cancer (SCLC)Histopathologically confirmed Kidney cancerHistopathologically confirmed Liver cancer

ACTRN12618001337268The First Teaching Hospital, Inner Mongolia Medical University50

Active, not recruiting

Phase 1

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients, affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

EUCTR2012-002554-23-ITOCTAPHARMA AG108

Active, not recruiting

Phase 1

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

EUCTR2012-002554-23-PLOCTAPHARMA AG108

Active, not recruiting

Phase 1

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 18.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

EUCTR2012-002554-23-HROCTAPHARMA AG108